Anti-tumor effects of progesterone in human glioblastoma multiforme: Role of PI3K/Akt/mTOR signaling

Journal of Steroid Biochemistry and Molecular Biology

Volumn 146, Issue , 2015, Pages 62-73

  Atif, Fahim ^a   Yousuf, Seema ^a   Stein, Donald G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; Progesterone; Treatment; Tumor

Indexed keywords

CASPASE 3; GELATINASE B; MAMMALIAN TARGET OF RAPAMYCIN; MIFEPRISTONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR GROWTH; TUMOR VASCULARIZATION; XENOGRAFT; ANIMAL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PROGESTERONE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918536817     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.04.007     Document Type: Article

References (51)

1. C. Adamson, O.O. Kanu, A.I. Mehta, C. Di, N. Lin, A.K. Mattox, D.D. Bigner, Glioblastoma multiforme: a review of where we have been and where we are going, Exp. Opin. Investig. Drugs 18 (2009) 1061-1083.
2. M. Westphal, D.C. Hilt, E. Bortey, P. Delavault, R. Olivares, P.C. Warnke, I.R. Whittle, J. Jaaskelainen, Z. Ram, A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neuro Oncol. 5 (2003) 79-88.
3. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, R.O. Mirimanoff, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med. 352 (2005) 987-996.
4. M.R. Gilbert, J.J. Dignam, T.S. Armstrong, J.S. Wefel, D.T. Blumenthal, M.A. Vogelbaum, H. Colman, A. Chakravarti, S. Pugh, M. Won, R. Jeraj, P.D. Brown, K.A. Jaeckle, D. Schiff, V.W. Stieber, D.G. Brachman, M. Werner-Wasik, I.W. Tremont-Lukats, E.P. Sulman, K.D. Aldape, W.J. Curran Jr., M.P. Mehta, A randomized trial of bevacizumab for newly diagnosed glioblastoma, N. Engl. J. Med. 370 (2014) 699-708.
5. M.A. Moroz, R. Huang, T. Kochetkov, W. Shi, H. Thaler, E. de Stanchina, I. Gamez, R.P. Ryan, R.G. Blasberg, Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas, Clin. Cancer Res. 17 (2011) 3282-3292.
6. T. Wirth, H. Samaranayake, J. Pikkarainen, A.M. Maatta, S. Yla-Herttuala, Clinical trials for glioblastoma multiforme using adenoviral vectors, Curr. Opin. Mol. Ther. 11 (2009) 485-492.
7. A.S. Jakola, S. Gulati, C. Weber, G. Unsgard, O. Solheim, Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study, PLoS ONE 6 (2011) e28592.
8. M.J. McGirt, D. Mukherjee, K.L. Chaichana, K.D. Than, J.D. Weingart, A. Quinones-Hinojosa, Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme, Neurosurgery 65 (2009) 463-469, discussion 469-470.
9. D.G. Stein, Is progesterone a worthy candidate as a novel therapy for traumatic brain injury? Dialogues Clin. Neurosci. 13 (2011) 352-359.
10. D.W. Wright, A.L. Kellermann, V.S. Hertzberg, P.L. Clark, M. Frankel, F.C. Goldstein, J.P. Salomone, L.L. Dent, O.A. Harris, D.S. Ander, D.W. Lowery, M.M. Patel, D.D. Denson, A.B. Gordon, M.M. Wald, S. Gupta, S.W. Hoffman, D.G. Stein, Pro-TECT: a randomized clinical trial of progesterone for acute traumatic brain injury, Ann. Emerg. Med. 49 (2007) 391-402.
11. G. Xiao, J. Wei, W. Yan, W. Wang, Z. Lu, Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial, Crit. Care 12 (2008) R61.
12. S.Z. Bu, D.L. Yin, X.H. Ren, L.Z. Jiang, Z.J. Wu, Q.R. Gao, G. Pei, Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines, Cancer 79 (1997) 1944-1950.
13. B. Formby, T.S. Wiley, Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis, Mol. Cell. Biochem. 202 (1999) 53-61.
14. K. Horita, N. Inase, S. Miyake, B. Formby, H. Toyoda, Y. Yoshizawa, Progesterone induces apoptosis in malignant mesothelioma cells, Anticancer Res. 21 (2001) 3871-3874.
15. D. Medina, F.S. Kittrell, A. Tsimelzon, S.A. Fuqua, Inhibition ofmammarytumorigenesis by estrogen and progesterone in genetically engineered mice, in: Ernst Schering Foundation Symposium Proceedings, 2007, pp. 109-126.
16. F. Atif, I. Sayeed, S. Yousuf, T. Ishrat, F. Hua, J. Wang, D.J. Brat, D.G. Stein, Progesterone inhibits the growth of human neuroblastoma: in vitro and in vivo evidence, Mol. Med. 17 (2011) 1084-1094.
17. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S.I. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S.H. Bigner, B.C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M.H. Wigler, R. Parsons, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, Science 275 (1997) 1943-1947.
18. J.S. Smith, I. Tachibana, S.M. Passe, B.K. Huntley, T.J. Borell, N. Iturria, J.R. O'Fallon, P.L. Schaefer, B.W. Scheithauer, C.D. James, J.C. Buckner, R.B. Jenkins, PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme, J. Natl. Cancer Inst. 93 (2001) 1246-1256.
19. T.A. Libermann, H.R. Nusbaum, N. Razon, R. Kris, I. Lax, H. Soreq, N. Whittle, M.D. Waterfield, A. Ullrich, J. Schlessinger, Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin, Nature 313 (1985) 144-147.
20. A.J. Ekstrand, N. Sugawa, C.D. James, V.P. Collins, Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4309-4313.
21. B. Lal, C.R. Goodwin, Y. Sang, C.A. Foss, K. Cornet, S. Muzamil, M.G. Pomper, J. Kim, J. Laterra, EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts, Mol. Cancer Ther. 8 (2009) 1751-1760.
22. C. Dos Santos, R. Karaky, D. Renoir, Y. Hamma-Kourbali, P. Albanese, E. Gobbo, F. Griscelli, P. Opolon, S. Dalle, M. Perricaudet, J. Courty, J. Delbe, Antitumorigenic effects of a mutant of the heparin affin regulatory peptide on the U87MG glioblastoma cell line, Int. J. Cancer 127 (2010) 1038-1051.
23. J. George, N.L. Banik, S.K. Ray, Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo, Neuro Oncol. 12 (2010) 1088-1101.
24. D. Koul, R. Shen, Y.W. Kim, Y. Kondo, Y. Lu, J. Bankson, S.M. Ronen, D.L. Kirkpatrick, G. Powis, W.K. Yung, Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma, Neuro Oncol. 12 (2010) 559-569.
25. H. Chen, L. Mei, L. Zhou, X. Shen, C. Guo, Y. Zheng, H. Zhu, Y. Zhu, L. Huang, PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts, J. Neurooncol. 104 (2011) 155-167.
26. B.C. McFarland, J.Y. Ma, C.P. Langford, G.Y. Gillespie, H. Yu, Y. Zheng, S.E. Nozell, D. Huszar, E.N. Benveniste, Therapeutic potential of AZD1480 for the treatment of human glioblastoma, Mol. Cancer Ther. 10 (2011) 2384-2393.
27. M. Endres, D. Biniszkiewicz, R.W. Sobol, C. Harms, M. Ahmadi, A. Lipski, J. Katchanov, P. Mergenthaler, U. Dirnagl, S.H. Wilson, A. Meisel, R. Jaenisch, Increased postischemic brain injury in mice deficient in uracil-DNA glycosylase, J. Clin. Invest. 113 (2004) 1711-1721.
28. T. Van Maerken, L. Ferdinande, J. Taildeman, I. Lambertz, N. Yigit, L. Vercruysse, A. Rihani, M. Michaelis, J. Cinatl Jr., C.A. Cuvelier, J.C. Marine, A. De Paepe, M. Bracke, F. Speleman, J. Vandesompele, Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wildtype p53, J. Natl. Cancer Inst. 101 (2009) 1562-1574.
29. A. Carmo, H. Carvalheiro, I. Crespo, I. Nunes, M.C. Lopes, Effect of temozolomide on the U-118 glioma cell line, Oncol. Lett. 2 (2011) 1165-1170.
30. D. Maier, G. Jones, X. Li, A.H. Schonthal, O. Gratzl, E.G. Van Meir, A. Merlo, The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells, Cancer Res. 59 (1999) 5479-5482.
31. M. Schumacher, C. Mattern, A. Ghoumari, J.P. Oudinet, P. Liere, F. Labombarda, R. Sitruk-Ware, A.F. De Nicola, R. Guennoun, Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors, Prog. Neurobiol. 113 (2014) 6-39.
32. R. Fjelldal, B.T. Moe, A. Orbo, G. Sager, MCF-7 cell apoptosis and cell cycle arrest: non-genomic effects of progesterone and mifepristone (RU-486), Anticancer Res. 30 (2010) 4835-4840.
33. B.T. Moe, A.B. Vereide, A. Orbo, R. Jaeger, G. Sager, Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy, Anticancer Res. 29 (2009) 1047-1052.
34. R. Ramaswamy, K. Ashton, R. Lea, P. Roberts, C.H. Davis, A. Golash, T. Dawson, Study of effectiveness of mifepristone for glioma cell line growth suppression, Br. J. Neurosurg. 26 (2012) 336-339.
35. L. Wang, W. Zhao, F. Leng, J. Ge, Z. Bu, Y. Zhang, P. Liu, Glucocorticoid receptors take part in the apoptotic process of human lens epithelial cells, but the glucocorticoid receptor antagonist RU486 does not rescue the cells fully, Mol. Biosyst. 7 (2011) 1926-1937.
36. D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (2011) 646-674.
37. T.T. Batchelor, D.G. Duda, E. di Tomaso, M. Ancukiewicz, S.R. Plotkin, E. Gerstner, A.F. Eichler, J. Drappatz, F.H. Hochberg, T. Benner, D.N. Louis, K.S. Cohen, H. Chea, A. Exarhopoulos, J.S. Loeffler, M.A. Moses, P. Ivy, A.G. Sorensen, P.Y. Wen, R.K. Jain, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma, J. Clin. Oncol. 28 (2010) 2817-2823.
38. M. Nakada, Y. Okada, J. Yamashita, The role of matrix metalloproteinases in glioma invasion, Front. Biosci. 8 (2003) e261-e269.
39. G.H. Vince, S. Wagner, T. Pietsch, R. Klein, R.H. Goldbrunner, K. Roosen, J.C. Tonn, Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas, Int. J. Dev. Neurosci. 17 (1999) 437-445.
40. C. Munaut, A. Noel, O. Hougrand, J.M. Foidart, J. Boniver, M. Deprez, Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas, Int. J. Cancer 106 (2003) 848-855.
41. W. Yan, W. Zhang, L. Sun, Y. Liu, G. You, Y. Wang, C. Kang, Y. You, T. Jiang, Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme, Brain Res. 1411 (2011) 108-115.
42. J.J. Kim, E. Chapman-Davis, Role of progesterone in endometrial cancer, Semin. Reprod. Med. 28 (2010) 81-90.
43. P. Liu, H. Cheng, T.M. Roberts, J.J. Zhao, Targeting the phosphoinositide 3-kinase pathway in cancer, Nat. Rev. Drug Discov. 8 (2009) 627-644.
44. Y. Hirose, M.S. Berger, R.O. Pieper, p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells, Cancer Res. 61 (2001) 1957-1963.
45. M. Kanazawa, H. Igarashi, K. Kawamura, T. Takahashi, A. Kakita, H. Takahashi, T. Nakada, M. Nishizawa, T. Shimohata, Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment, J. Cereb. Blood Flow Metab. 31 (2011) 1461-1474.
46. Y. Hirose, M. Katayama, O.K. Mirzoeva, M.S. Berger, R.O. Pieper, Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence, Cancer Res. 65 (2005) 4861-4869.
47. M. Singh, C. Su, S. Ng, Non-genomic mechanisms of progesterone action in the brain, Front. Neurosci. 7 (2013) 159.
48. Y. Zhu, J. Bond, P. Thomas, Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor, Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 2237-2242.
49. G.E. Dressing, P. Thomas, Identification of membrane progestin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer, Steroids 2 (2007) 111-116.
50. L. Zuo, W. Li, S. You, Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway, Breast Cancer Res. 12 (2010) R34.
51. P. Thomas, Y. Pang, Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells, Neuroendocrinology 96 (2012) 162-171.